The 10-Year Showdown: Sleeve Gastrectomy or Gastric Bypass

Clinician's Perspective:

• Superior Weight Maintenance: In the per-protocol analysis (only including patients who kept their original surgical anatomy), Roux-en-Y Gastric Bypass (RYGB) achieved a 65.9% excess body mass index loss compared to 56.1% for Sleeve Gastrectomy (SG) after 10 years.

• High Conversion Rates: Nearly 30% of patients who initially underwent a Sleeve Gastrectomy (32 out of 107 participants) required a second operation to convert to a different procedure, often due to severe reflux or insufficient weight loss.

• The Reflux Factor: Among patients with no prior history of heartburn, 32.3% of those in the Sleeve Gastrectomy group developed de novo (newly developed) Gastroesophageal Reflux Disease (GERD) a decade later, compared to just 7.9% in the Bypass group.

• Diabetes Remission: Both procedures proved highly effective for metabolic health, with 61.1% of Sleeve patients and 71.4% of Bypass patients maintaining complete remission of Type 2 diabetes at the 10-year mark.

• Long-Term Safety Profile: Despite the complexity of the surgeries, there was no significant difference in the Comprehensive Complication Index (a validated scale for surgical morbidity) between the two groups over the decade.

• Quality of Life Gains: Both groups reported a significant and sustained increase in their Moorehead-Ardelt Quality of Life scores, rising from near-neutral baseline levels to "good" clinical outcomes after 10 years.

When choosing a weight-loss surgery, many people ask, "Which one is better? " .

The SM-BOSS (Swiss Multicenter Bypass or Sleeve Study) studied 217 participants with severe obesity (average baseline BMI of 43.9) for 10 years to compare the two most common surgical procedures: the Laparoscopic Sleeve Gastrectomy (SG) and the Laparoscopic Roux-en-Y Gastric Bypass (RYGB). It turns out that while both are great, they have very different long-term "personalities."

The Weight Loss Divergence

At first glance, both surgeries look similar. But when researchers looked only at patients who kept their original surgery for the full 10 years, the Gastric Bypass was the winner. Bypass patients lost about 10% more of their excess weight than those with the Sleeve Gastrectomy.

This divergence is largely explained by the "conversion rate." Over 10 years, 29.9% of the Sleeve group required a conversion to a different anatomy (usually a Bypass), whereas only 5.5% of the Bypass group required a revision. This suggests that while a Sleeve is effective for many, it carries a higher probability of requiring a secondary surgical intervention to maintain long-term results or manage side effects.

Metabolic Success and the Reflux Challenge

Both surgeries performed exceptionally well in treating obesity-related comorbidities (co-existing medical conditions). Remission rates for Type 2 diabetes remained high across the cohort, and significant improvements were noted in arterial hypertension (high blood pressure) and obstructive sleep apnea (breathing interruptions during sleep).

A critical point of differentiation emerged regarding Gastroesophageal Reflux Disease (GERD). This is one of the most important findings for patients to know. The Sleeve Gastrectomy may lead to heartburn. About 1 in 3 patients who had no reflux before their Sleeve ended up with "new-onset" reflux years later. On the other hand, the Gastric Bypass is often called the "gold standard" for fixing reflux. If you already suffer from bad heartburn, the Bypass is usually the safer bet for your long-term comfort.

Stability in Safety and Satisfaction

The good news is that both surgeries are "metabolic powerhouses." Even 10 years later, the majority of patients in both groups (over 60–70%) were in complete remission from Type 2 diabetes. Both surgeries also significantly improved high blood pressure and sleep apnea. It is of note, each type of procedure has a different risk profile.

Ultimately, the data suggests that while both surgeries are potent tools for weight management, the Gastric Bypass may offer a more definitive, "one-and-done" solution for a larger proportion of patients over a 10-year horizon. However, before making any decision, it is important to discuss with your healthcare provider to see which procedure is more appropriate for you.

Evidence Strength: This is a high-quality randomized clinical trial with 10-year longitudinal data, though it is slightly limited by a 35% loss to follow-up and insufficient power for some secondary metabolic outcomes. Final Rating: ★★★★☆

Source: Read the full study